{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:59:42Z","timestamp":1791529182468,"version":"4.3.4"},"reference-count":50,"publisher":"Becaris Publishing Limited","issue":"9","funder":[{"name":"Novartis Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5\u00a0years following switch from commonly used first-line therapies.\n            <jats:bold>Results:<\/jats:bold>\n            Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and\u00a0natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.\n          <\/jats:p>","DOI":"10.57264\/cer-2022-0175","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T15:21:37Z","timestamp":1692717697000},"source":"Crossref","is-referenced-by-count":6,"title":["Cost\u2013consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada"],"prefix":"10.57264","volume":"12","author":[{"given":"Virender","family":"Bhan","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, BC, V6T 2B5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser","family":"Clift","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial University of Newfoundland, St. John's, NL, A1B 3V6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moogeh","family":"Baharnoori","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology, Queen's University, Kingston, ON, K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Thomas","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barkha P","family":"Patel","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Blanchette","sequence":"additional","affiliation":[{"name":"Novartis Canada Inc., Dorval, QC, H9S 1A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Adlard","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel,4056, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umakanth","family":"Vudumula","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited, Dublin, D04 NN12, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Gudala","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad, 500081, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikkita","family":"Dutta","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grima","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON, L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souka\u00efna","family":"Mouallif","sequence":"additional","affiliation":[{"name":"Novartis Canada Inc., Dorval, QC, H9S 1A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatine","family":"Farhane","sequence":"additional","affiliation":[{"name":"Novartis Canada Inc., Dorval, QC, H9S 1A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban X","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 24(2), 96\u2013120 (2018).","journal-title":"Mult. Scler."},{"issue":"2","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/nmt-2020-0010","article-title":"Multiple sclerosis and related challenges to young women's health: canadian expert review","volume":"10","author":"Vorobeychik G","year":"2020","unstructured":"Vorobeychik G, Black D, Cooper P, Cox A. Multiple sclerosis and related challenges to young women's health: canadian expert review. Neurodegener. Dis. Manag. 10(Suppl. 2), 1\u201313 (2020).","journal-title":"Neurodegener. Dis. Manag."},{"issue":"2","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MRR.0b013e32835c79ea","article-title":"Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002\u20132011 literature","volume":"36","author":"Schiavolin S","year":"2013","unstructured":"Schiavolin S, Leonardi M, Giovannetti AM Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002\u20132011 literature. Int. J. Rehabil. Res. 36(2), 105\u2013111 (2013).","journal-title":"Int. J. Rehabil. Res."},{"issue":"5","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13696998.2016.1277229","article-title":"Employment and absenteeism in working-age persons with multiple sclerosis","volume":"20","author":"Salter A","year":"2017","unstructured":"Salter A, Thomas N, Tyry T, Cutter G, Marrie RA. Employment and absenteeism in working-age persons with multiple sclerosis. J. Med. Econ. 20(5), 493\u2013502 (2017).","journal-title":"J. Med. Econ."},{"issue":"5","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1155\/2013\/829464","article-title":"Does pain in individuals with multiple sclerosis affect employment? A systematic review and meta-analysis","volume":"18","author":"Shahrbanian S","year":"2013","unstructured":"Shahrbanian S, Auais M, Duquette P, Andersen K, Mayo NE. Does pain in individuals with multiple sclerosis affect employment? A systematic review and meta-analysis. Pain Res. Manag. 18(5), e94\u2013e100 (2013).","journal-title":"Pain Res. Manag."},{"issue":"6","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00415-009-5441-7","article-title":"Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management","volume":"257","author":"Simmons RD","year":"2010","unstructured":"Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J. Neurol. 257(6), 926\u2013936 (2010).","journal-title":"J. Neurol."},{"issue":"7","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/1352458518781971","article-title":"Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis","volume":"25","author":"Chen J","year":"2019","unstructured":"Chen J, Taylor B, Palmer AJ Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult. Scler. 25(7), 994\u20131004 (2019).","journal-title":"Mult. Scler."},{"issue":"2","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/135245850000600207","article-title":"Cost and health related quality of life consequences of multiple sclerosis","volume":"6","author":"Grima DT","year":"2000","unstructured":"Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 6(2), 91\u201398 (2000).","journal-title":"Mult. Scler."},{"issue":"18","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"e1810","DOI":"10.1212\/WNL.0000000000200150","article-title":"The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs","volume":"98","author":"Bebo B","year":"2022","unstructured":"Bebo B, Cintina I, Larocca N The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. Neurology 98(18), e1810\u2013e1817 (2022).","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1017\/cjn.2020.66","article-title":"Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations","volume":"47","author":"Freedman MS","year":"2020","unstructured":"Freedman MS, Devonshire V, Duquette P Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can. J. Neurol. Sci. 47(4), 437\u2013455 (2020).","journal-title":"Can. J. Neurol. Sci."},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0267"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0122"},{"issue":"4","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","article-title":"Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis","volume":"15","author":"Scolding N","year":"2015","unstructured":"Scolding N, Barnes D, Cader S Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract. Neurol. 15(4), 273\u2013279 (2015).","journal-title":"Pract. Neurol."},{"issue":"4","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He A","year":"2020","unstructured":"He A, Merkel B, Brown JWL Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19(4), 307\u2013316 (2020).","journal-title":"Lancet Neurol."},{"issue":"3","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser SL","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N. Engl. J. Med. 376(3), 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser SL","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA Ofatumumab versus Teriflunomide in Multiple Sclerosis. N. Engl. J. Med. 383(6), 546\u2013557 (2020).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_7_19_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Procedures for CADTH Reimbursement Reviews. https:\/\/cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH_Drug_Reimbursement_Review_Procedures.pdf (April 2021)."},{"issue":"4","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3111\/13696998.2015.1135805","article-title":"cost\u2013effectiveness of delayed-release dimethyl fumarate compared with glatiramer acetate and fingolimod for the treatment of relapsing-remitting multiple sclerosis","volume":"19","author":"Mauskopf J","year":"2016","unstructured":"Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. cost\u2013effectiveness of delayed-release dimethyl fumarate compared with glatiramer acetate and fingolimod for the treatment of relapsing-remitting multiple sclerosis. J. Med. Econ. 19(4), 432\u2013442 (2016).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme M","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 10(1), 54\u201360 (2007).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_7_22_2","first-page":"248","article-title":"Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976\u20131980","volume":"65","author":"Patzold U","year":"1982","unstructured":"Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976\u20131980. Acta Neurol. Scand. 65(4), 248\u2013266 (1982).","journal-title":"Acta Neurol. Scand."},{"issue":"10","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"e75416","DOI":"10.1371\/journal.pone.0075416","article-title":"Multiple sclerosis susceptibility genes: associations with relapse severity and recovery","volume":"8","author":"Mowry EM","year":"2013","unstructured":"Mowry EM, Carey RF, Blasco MR Multiple sclerosis susceptibility genes: associations with relapse severity and recovery. PLoS One 8(10), e75416 (2013).","journal-title":"PLoS One"},{"key":"e_1_3_7_24_2","unstructured":"Statistics Canada (Web Page). Life tables Canada provinces and territories Table 13-10-0114-01 (2018\u20132020 qx column). https:\/\/www150.statcan.gc.ca\/n1\/en\/catalogue\/84-537-X (January 2022)."},{"issue":"2","key":"e_1_3_7_25_2","first-page":"101","article-title":"Long-term survival experience of patients with multiple sclerosis","volume":"29","author":"Pokorski RJ","year":"1997","unstructured":"Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J. Insur. Med. 29(2), 101\u2013106 (1997).","journal-title":"J. Insur. Med."},{"issue":"9","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1177\/1352458513518259","article-title":"Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis","volume":"20","author":"Cho JY","year":"2014","unstructured":"Cho JY, Hong KS, Kim HJ Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis. Mult. Scler. 20(9), 1217\u20131223 (2014).","journal-title":"Mult. Scler."},{"issue":"1","key":"e_1_3_7_27_2","first-page":"e11","article-title":"Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada","volume":"19","author":"Karampampa K","year":"2012","unstructured":"Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J. Popul. Ther. Clin. Pharmacol. 19(1), e11\u201325 (2012).","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"e_1_3_7_28_2","unstructured":"Government of Canada (Web Page). CPP Retirement Pension. https:\/\/www.canada.ca\/en\/services\/benefits\/publicpensions\/cpp\/cpp-benefit\/when-start.html (May 2022)."},{"issue":"2","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1191\/1352458505ms1137oa","article-title":"Cost of multiple sclerosis by level of disability: a review of literature","volume":"11","author":"Patwardhan MB","year":"2005","unstructured":"Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult. Scler. 11(2), 232\u2013239 (2005).","journal-title":"Mult. Scler."},{"key":"e_1_3_7_30_2","unstructured":"Ontario Case Costing Initiative (Web Page). Costing Analysis Tool. https:\/\/hsimi.ca\/occp\/occpreports\/ (2022)."},{"key":"e_1_3_7_31_2","unstructured":"Government of Ontario (Web Page). Ontario Drug Benefit Formulary. https:\/\/www.formulary.health.gov.on.ca\/formulary\/ (2022)."},{"key":"e_1_3_7_32_2","unstructured":"Ontario Ministry of Health (Web Page). Schedule of Benefits for Laboratory Services (Effective July 1 2020). http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf (2022)."},{"key":"e_1_3_7_33_2","unstructured":"Government of Ontario (Web Page). Ontario Exceptional Access Program Formulary. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/odbf\/odbf_except_access.aspx (2022)."},{"key":"e_1_3_7_34_2","unstructured":"Ontario Ministry of Health (Web Page). Schedule of Benefits Physician Services Under the Health Insurance Act (Effecive March 14 2021). http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master20200306.pdf (2022)."},{"issue":"2","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3747\/co.20.1223","article-title":"cost\u2013effectiveness of systemic therapies for metastatic pancreatic cancer","volume":"20","author":"Tam VC","year":"2013","unstructured":"Tam VC, Ko YJ, Mittmann N cost\u2013effectiveness of systemic therapies for metastatic pancreatic cancer. Curr. Oncol. 20(2), e90\u2013e106 (2013).","journal-title":"Curr. Oncol."},{"key":"e_1_3_7_36_2","unstructured":"Government of Alberta (Web Page) Alberta interactive drug benefit list. https:\/\/idbl.ab.bluecross.ca\/idbl\/load.do (2022)."},{"issue":"6","key":"e_1_3_7_37_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","article-title":"cost\u2013effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada","volume":"6","author":"Baharnoori M","year":"2022","unstructured":"Baharnoori M, Bhan V, Clift F cost\u2013effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. PharmacoEconomics-Open 6(6), 859\u2013870 (2022).","journal-title":"PharmacoEconomics-Open"},{"issue":"1","key":"e_1_3_7_38_2","article-title":"Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: a cost-consequence analysis from a societal perspective in Germany","volume":"8","author":"Koeditz D","year":"2022","unstructured":"Koeditz D, Frensch J, Bierbaum M Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: a cost-consequence analysis from a societal perspective in Germany. Mult. Scler. J. Exp. Transl. Clin. 8(1), DOI: 10.1177\/20552173221085741 (2022).","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"10","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/13696998.2017.1357564","article-title":"Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon \u03b2-1a","volume":"20","author":"Frasco MA","year":"2017","unstructured":"Frasco MA, Shih T, Incerti D, Diaz Espinosa O, Vania DK, Thomas N. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon \u03b2-1a. J. Med. Econ. 20(10), 1074\u20131082 (2017).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-019-4264-1","article-title":"cost\u2013effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy","volume":"19","author":"Furneri G","year":"2019","unstructured":"Furneri G, Santoni L, Ricella C, Prosperini L. cost\u2013effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy. BMC Health Serv. Res. 19(1), 1\u20139 (2019).","journal-title":"BMC Health Serv. Res."},{"issue":"10","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/13696998.2017.1355310","article-title":"cost\u2013effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis","volume":"20","author":"Yang H","year":"2017","unstructured":"Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. cost\u2013effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J. Med. Econ. 20(10), 1056\u20131065 (2017).","journal-title":"J. Med. Econ."},{"issue":"2","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2018.08.002","article-title":"Association between disability, cognition, fatigue, EQ-5D-3L domains, and utilities estimated with different Western European value sets in patients with multiple sclerosis","volume":"22","author":"Eriksson J","year":"2019","unstructured":"Eriksson J, Kobelt G, Gannedahl M, Berg J. Association between disability, cognition, fatigue, EQ-5D-3L domains, and utilities estimated with different Western European value sets in patients with multiple sclerosis. Value Health 22(2), 231\u2013238 (2019).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt G","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J New insights into the burden and costs of multiple sclerosis in Europe. Mult. Scler. 23(8), 1123\u20131136 (2017).","journal-title":"Mult. Scler."},{"issue":"2","key":"e_1_3_7_44_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S0317167100053403","article-title":"Short term predictors of unemployment in multiple sclerosis patients","volume":"30","author":"Busche K","year":"2003","unstructured":"Busche K, Fisk J, Murray T, Metz L. Short term predictors of unemployment in multiple sclerosis patients. Can. J. Neurol. Sci. 30(2), 137\u2013142 (2003).","journal-title":"Can. J. Neurol. Sci."},{"issue":"11","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00415-015-7853-x","article-title":"Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis","volume":"262","author":"Tauhid S","year":"2015","unstructured":"Tauhid S, Chu R, Sasane R Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J. Neurol. 262(11), 2425\u20132432 (2015).","journal-title":"J. Neurol."},{"issue":"1","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/WOR-203254","article-title":"Personal, health and function, and career maintenance factors as determinants of quality of life among employed people with multiple sclerosis","volume":"67","author":"Rumrill P","year":"2020","unstructured":"Rumrill P, Li J, Strauser D Personal, health and function, and career maintenance factors as determinants of quality of life among employed people with multiple sclerosis. Work 67(1), 81\u201394 (2020).","journal-title":"Work"},{"issue":"6","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7224\/1537-2073.2016-016","article-title":"Barriers to the accessibility and continuity of health-care services in people with multiple sclerosis: a literature review","volume":"19","author":"Chiu C","year":"2017","unstructured":"Chiu C, Bishop M, Pionke J, Strauser D, Santens RL. Barriers to the accessibility and continuity of health-care services in people with multiple sclerosis: a literature review. Int. J. MS Care 19(6), 313\u2013321 (2017).","journal-title":"Int. J. MS Care"},{"issue":"6","key":"e_1_3_7_48_2","first-page":"S151","article-title":"Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management","volume":"22","author":"Owens GM","year":"2016","unstructured":"Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am. J. Manag. Care 22(Suppl. 6), S151\u2013S158 (2016).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_7_49_2","unstructured":"Statistics Canada (Web Page). Consumer Price Index [Health care] monthly not seasonally adjusted; Table 18-10-0004-01. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000401 (2022)."},{"issue":"5","key":"e_1_3_7_50_2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding K","year":"2019","unstructured":"Harding K, Williams O, Willis M Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 76(5), 536\u2013541 (2019).","journal-title":"JAMA Neurol."},{"issue":"5","key":"e_1_3_7_51_2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4097\/kja.21358","article-title":"Concepts and emerging issues of network meta-analysis","volume":"74","author":"Ahn E","year":"2021","unstructured":"Ahn E, Kang H. Concepts and emerging issues of network meta-analysis. Korean J. Anesthesiol. 74(5), 371\u2013382 (2021).","journal-title":"Korean J. Anesthesiol."},{"key":"e_1_3_7_52_2","volume-title":"NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials.","author":"Dias S","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence (NICE), Royston, UK (2011)."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2022-0175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T18:37:21Z","timestamp":1693507041000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2022-0175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.57264\/cer-2022-0175"],"URL":"https:\/\/doi.org\/10.57264\/cer-2022-0175","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"article-number":"e220175"}}